TABLE 3.
Susceptibility of P. aeruginosa isolates to antimicrobial agents according to specimen source (data from 1999 to 2002 combined)
| Antimicrobial agent(s) | Specimen source | Total no. of isolates | % Sa | % Ia | % Ra |
|---|---|---|---|---|---|
| Amikacin | Blood or bone marrow | 1,897 | 90.0 | 4.2 | 5.7 |
| Lower respiratory tractb | 20,007 | 83.1 | 6.0 | 10.9 | |
| Upper respiratory tractc | 1,370 | 93.0 | 3.2 | 3.8 | |
| Wound | 12,111 | 94.1 | 2.6 | 3.3 | |
| Cefepime | Blood or bone marrow | 1,897 | 76.5 | 12.3 | 11.1 |
| Lower respiratory tract | 20,007 | 69.3 | 18.0 | 12.7 | |
| Upper respiratory tract | 1,370 | 91.2 | 6.0 | 2.8 | |
| Wound | 12,111 | 81.0 | 10.9 | 8.1 | |
| Ceftazidime | Blood or bone marrow | 1,897 | 77.1 | 9.0 | 13.9 |
| Lower respiratory tract | 20,007 | 71.5 | 11.4 | 17.1 | |
| Upper respiratory tract | 1,370 | 94.4 | 2.5 | 3.1 | |
| Wound | 12,111 | 79.7 | 8.2 | 12.1 | |
| Ciprofloxacin | Blood or bone marrow | 1,897 | 68.7 | 4.7 | 26.6 |
| Lower respiratory tract | 20,007 | 56.6 | 9.9 | 33.5 | |
| Upper respiratory tract | 1,370 | 85.2 | 5.1 | 9.7 | |
| Wound | 12,111 | 68.4 | 5.2 | 26.4 | |
| Gentamicin | Blood or bone marrow | 1,897 | 74.6 | 7.7 | 17.6 |
| Lower respiratory tract | 20,007 | 63.6 | 12.4 | 24.0 | |
| Upper respiratory tract | 1,370 | 85.1 | 6.8 | 8.1 | |
| Wound | 12,111 | 79.3 | 7.0 | 13.7 | |
| Imipenem | Blood or bone marrow | 1,897 | 78.5 | 4.3 | 17.2 |
| Lower respiratory tract | 20,007 | 72.4 | 8.4 | 19.2 | |
| Upper respiratory tract | 1,370 | 94.5 | 1.6 | 3.9 | |
| Wound | 12,111 | 83.0 | 5.2 | 11.8 | |
| Piperacillin | Blood or bone marrow | 1,897 | 83.1 | -d | 16.9 |
| Lower respiratory tract | 20,007 | 79.2 | - | 20.8 | |
| Upper respiratory tract | 1,370 | 96.4 | - | 3.6 | |
| Wound | 12,111 | 85.4 | - | 14.6 | |
| Piperacillin-tazobactam | Blood or bone marrow | 1,897 | 88.8 | - | 11.2 |
| Lower respiratory tract | 20,007 | 85.4 | - | 14.6 | |
| Upper respiratory tract | 1,370 | 97.5 | - | 2.5 | |
| Wound | 12,111 | 89.6 | - | 10.4 | |
| Ticarcillin-clavulanate | Blood or bone marrow | 1,897 | 70.2 | - | 29.8 |
| Lower respiratory tract | 20,007 | 64.0 | - | 36.0 | |
| Upper respiratory tract | 1,370 | 91.2 | - | 8.8 | |
| Wound | 12,111 | 71.9 | - | 28.1 | |
| Tobramycin | Blood or bone marrow | 1,897 | 85.0 | 1.3 | 13.7 |
| Lower respiratory tract | 20,007 | 81.5 | 3.1 | 15.4 | |
| Upper respiratory tract | 1,370 | 94.3 | 2.3 | 3.4 | |
| Wound | 12,111 | 88.7 | 1.4 | 9.9 |
a
The percentages of susceptible (S), intermediate (I), and resistant (R) isolates according to NCCLS breakpoints are shown.
b
Includes bronchus, brush biopsy, bronchus wash, sputum, tracheal aspirate, bronchoalveolar lavage, tracheostomy, transtracheal aspirate, lung, lung abscess, pleural biopsy, pleural fluid, and thoracentesis specimens.
c
Includes sinus, ear, tonsil, tympanocentesis, oral, maxilla, and mandible specimens and nasopharynx, throat, or nose, specimens.
d
-, NCCLS breakpoints for the intermediate category unavailable.